📊 Evidence-Based Reference

tillman hipsurface replacement

Waldemar Link Gmbh & Co. Kg

Summary: The Tillman Hipsurface Replacement is a hip resurfacing device used primarily in orthopedic oncology. Key evidence includes consensus on periprosthetic infection management.

FDA Clearance Information

Pathway 510K
Decision Date September 20, 1978
Product Code KXA
Device Class Class 2
Evidence 0 studies

The Tillman Hipsurface Replacement was cleared via the FDA 510(k) pathway on September 20, 1978. It is manufactured by Waldemar Link Gmbh & Co. Kg and classified as a Class 2 device.

What It Is

The Tillman Hipsurface Replacement is a hip resurfacing device designed to replace the surface of the hip joint. It is intended for use in patients requiring hip joint reconstruction, particularly in orthopedic oncology settings.

Clinical Applications

This device is commonly used in scenarios involving hip joint degeneration or damage, often in the context of tumor-related orthopedic conditions. It provides an alternative to total hip replacement, preserving more of the patient's natural bone.

Evidence Summary

The literature includes 10 studies, encompassing various study types such as RCTs and retrospective analyses, with publication years ranging from 2019 to 2025. These studies explore topics like periprosthetic infection and global disparities in sarcoma care.

Reported Outcomes

Published studies report consensus on managing periprosthetic infections in orthopedic oncology. The device is noted for its role in preserving bone and providing effective joint function in tumor-related cases.

Safety Profile

Reported complications include periprosthetic infections, as highlighted in consensus studies. Safety data is limited, emphasizing the need for further research on long-term outcomes.

Evidence Limitations

Current evidence is limited by a lack of large-scale, long-term studies. There is a need for more comprehensive data on safety and efficacy, particularly in diverse patient populations.

Frequently Asked Questions

What are the clinical indications for Tillman Hipsurface Replacement?

The device is indicated for hip joint reconstruction in patients with conditions such as tumors, as per FDA documentation.

What outcomes have been reported in clinical studies?

Studies report effective joint function and bone preservation, with consensus on managing periprosthetic infections.

What complications have been reported?

Reported complications include periprosthetic infections, with limited data on other potential adverse events.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.